Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
about
Targeting of PBP1 by β-lactams determines recA/SOS response activation in heterogeneous MRSA clinical strainsEvaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin ActivityDaptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycinClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patientsCurrent and novel antibiotics against resistant Gram-positive bacteriaFrequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial PeptidesTelavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin SynergyMechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.Role of the LytSR two-component regulatory system in adaptation to cationic antimicrobial peptides in Staphylococcus aureusMulticenter study of high-dose daptomycin for treatment of enterococcal infectionsA multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Daptomycin: pharmacology and clinical use.Modeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing Klebsiella pneumoniae Strains with Unusually Low Carbapenem MICs.Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardaptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetationsNovel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activityImpact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy.Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.
P2860
Q28486717-79308547-1835-4B24-8700-453A942182FAQ33939055-F3D21604-D1D7-4E87-929D-9F69C18276EFQ34045273-B75B132A-A2D1-4BA7-8207-AE73470BA235Q34116509-E2DACA8F-11F2-4B1D-94BA-139001D07F10Q34157657-BB63B775-DCFE-47A7-95BE-CA8EE4814053Q34573702-DA213E17-6F41-4E13-8D6A-E176E28F4F6CQ35026521-CAA8A90A-D1F6-4B83-B098-BBAE97DEE123Q35860154-E9FE7FDE-053F-4EC6-855B-271213906EE6Q36364106-F2897261-2A82-4350-A6B1-9C12C4A1786BQ36396117-7C1E9E35-7B66-4939-A1E0-8EEFFA596A02Q36439093-93E3A693-270D-455E-BFE9-D23EB4DD9E16Q36565462-F383767B-AAE6-40D8-9AD4-35B345BFD9F1Q37036548-9BAFCAD1-B5E5-4058-8489-634EF23327D9Q37124177-014239EC-D5BA-41DD-BE3A-5E855E1974DFQ37286911-FE6BC3FF-31A7-4C49-A7AB-08F0144884B3Q37377897-1A67C49D-3BDA-4E01-9644-F9C886AAF601Q37693931-8B71E83C-8232-4BAC-A582-C1A3ABC01D19Q40662901-D1FDE69D-C3E9-44B1-9B7D-8A3AC66950AEQ41570351-D8A8C1F1-5AC7-41F9-BD26-A0888C146055Q42197385-5D8D4451-3AFD-4028-AE17-D4F9264302CDQ42363645-CB91C640-F195-4E00-8F31-6B8CF4571DCEQ42445383-EB30E7C5-2501-4BAF-936D-71CE146934C0Q42586714-54D75D3E-ED8D-40A4-A8B7-71A93D22F65DQ42696736-2BE96851-F9EB-442E-BBC3-FE575925CB94Q42727129-E77DF325-CF61-45AB-9F47-0A331FB6FBABQ42789679-5C2B6BF2-4626-417F-A716-7E079A88EFA2Q42854012-22ABB778-B0DA-450D-B5B2-9D5350DA64D9Q44579110-9CD4D954-82CC-48B7-83F0-8C8D8E94B643Q45936598-2B21E04F-2987-40E8-943A-563D5BD468EBQ47318913-BA0FE11C-6A6B-407E-A536-40558D58CC70
P2860
Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Evaluation of daptomycin treat ...... and current dosing strategies.
@en
Evaluation of daptomycin treat ...... and current dosing strategies.
@nl
type
label
Evaluation of daptomycin treat ...... and current dosing strategies.
@en
Evaluation of daptomycin treat ...... and current dosing strategies.
@nl
prefLabel
Evaluation of daptomycin treat ...... and current dosing strategies.
@en
Evaluation of daptomycin treat ...... and current dosing strategies.
@nl
P2093
P2860
P356
P1476
Evaluation of daptomycin treat ...... and current dosing strategies.
@en
P2093
Glenn W Kaatz
Michael J Rybak
Warren E Rose
P2860
P304
P356
10.1093/JAC/DKM170
P407
P577
2007-05-31T00:00:00Z